CN101255157B - Crystal system of chlorhydric acid palonosetron and preparation method thereof - Google Patents

Crystal system of chlorhydric acid palonosetron and preparation method thereof Download PDF

Info

Publication number
CN101255157B
CN101255157B CN2008100595276A CN200810059527A CN101255157B CN 101255157 B CN101255157 B CN 101255157B CN 2008100595276 A CN2008100595276 A CN 2008100595276A CN 200810059527 A CN200810059527 A CN 200810059527A CN 101255157 B CN101255157 B CN 101255157B
Authority
CN
China
Prior art keywords
crystal formation
pharmaceutical composition
content
palonosetron
mixed solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008100595276A
Other languages
Chinese (zh)
Other versions
CN101255157A (en
Inventor
陈学军
张海欧
李勇
徐飞虎
孙汉栋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HANGZHOU JIUYUAN GENE ENGINEERING Co Ltd
JIUYUAN GENE ENGINEERING Co Ltd HANGZHOU
Original Assignee
HANGZHOU JIUYUAN GENE ENGINEERING Co Ltd
JIUYUAN GENE ENGINEERING Co Ltd HANGZHOU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HANGZHOU JIUYUAN GENE ENGINEERING Co Ltd, JIUYUAN GENE ENGINEERING Co Ltd HANGZHOU filed Critical HANGZHOU JIUYUAN GENE ENGINEERING Co Ltd
Priority to CN2008100595276A priority Critical patent/CN101255157B/en
Publication of CN101255157A publication Critical patent/CN101255157A/en
Application granted granted Critical
Publication of CN101255157B publication Critical patent/CN101255157B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to two novel crystal forms of palonosetron hydrochloride that are A and B crystal forms. The A and B crystal forms have characteristic diffraction peaks when x-ray diffraction is used on the powder under Cu-K alpha radiation conditional (lamed=1. 54059) and the bragg 2theta angle between 0 and 50 degree C. The A crystal form has aendothermic peak near 320. 678 degree C, and the B crystal form has a endothermic peak near 320. 68 degree C after performed differential thermal analysis. Further the invention also relates to a process for preparing the crystal forms and pharmaceutical compositions containing the crystal forms.

Description

Crystal formation of a kind of RS 25259-197 and preparation method thereof
Technical field
The present invention relates to crystal formation, its preparation method of RS 25259-197 and contain the pharmaceutical composition of these crystal formations.
Background of invention
RS 25259-197 (Palonosetron hydrochloride, trade(brand)name Aloxi) is the selectivity 5-HT3 receptor antagonist of developing by Switzerland Helsinn company, chemistry is by name: (3aS)-2-[(3S)-1-azabicyclo [2.2.2] octyl]-2,3,3a, 4,5,6-six hydrogen-1-oxo-1H-phenylhydrazine [de] isoquinoline hydrochloride, its molecular structural formula is as follows.On July 25th, 2003, this product obtained FDA (FDA) approval, was used for the treatment of moderate or highly caused the acute and tardy property nausea and vomiting that vomitting property chemotherapy causes.
Figure S2008100595276D00011
RS 25259-197 is the 4th granted 5-HT 3Receptor antagonist.A key property of Palonosetron is a long half time, has 40 hours approximately, and other 5-HT 3The transformation period of receptor antagonist has only a few hours.And Palonosetron can optionally be attached to 5-HT 3On the acceptor, have stronger affinity, with the avidity of acceptor almost be other 5-HT 3100 times of antagonist.
Report that the earliest RS 25259-197 synthetic document is a U.S. Pat 5202333, this patent disclosure the application of medicinal compositions in vomiting that the treatment chemicotherapy causes, pain, gastrointestinal disturbance etc. of the preparation method of RS 25259-197 and hydrochloric Palonosetron.A kind of synthesis technique of new RS 25259-197 is disclosed in U.S. Pat 5510486 in addition.But the synthetic also reference Synthesis of relevant RS 25259-197,1996,7:816-818.
But above-mentioned these documents are the crystal formation and the preparation method of not mentioned RS 25259-197 all, the spectral response curve of more not mentioned relevant crystal formation.
Summary of the invention
The purpose of this invention is to provide a kind of new crystal, its preparation method of RS 25259-197 and contain the pharmaceutical composition of these crystal formations.
The invention discloses two new crystal of RS 25259-197, below be referred to as A type and Type B.Described A crystal formation is using Cu-K α radiation condition (λ=1.54059
Figure 2008100595276_32
), the powder x-ray diffraction when 2 θ angles are 0-50 ° in Prague has following characteristic peak: (d) is expressed as 7.32 with spacing
Figure 2008100595276_33
6.43
Figure 2008100595276_34
6.26
Figure 2008100595276_35
6.12 5.61
Figure 2008100595276_37
5.24
Figure 2008100595276_38
4.80
Figure 2008100595276_39
4.51
Figure 2008100595276_40
4.44
Figure 2008100595276_41
4.24
Figure 2008100595276_42
3.86
Figure 2008100595276_43
3.82
Figure 2008100595276_44
3.79 3.75 3.69
Figure 2008100595276_47
3.65
Figure 2008100595276_48
3.21
Figure 2008100595276_49
2.77
Described B crystal formation is using Cu-K α radiation condition (λ=1.54059
Figure 2008100595276_51
), the powder x-ray diffraction when 2 θ angles are 0-50 ° in Prague has following characteristic peak: (d) is expressed as 6.81 with spacing
Figure 2008100595276_52
6.46
Figure 2008100595276_53
6.25
Figure 2008100595276_54
5.76
Figure 2008100595276_55
5.49 5.05
Figure 2008100595276_57
4.81
Figure 2008100595276_58
4.45
Figure 2008100595276_59
3.83
Figure 2008100595276_60
3.65
Figure 2008100595276_61
3.58
Figure 2008100595276_62
3.55
Figure 2008100595276_63
3.23
Figure 2008100595276_64
2.83
Figure 2008100595276_65
Described Palonosetron A or B crystal formation are surveyed infrared absorption spectrum with the KCl pressed disc method, and its absorption peak is similar.Described A type is at about 3025cm -12924cm -12861cm -12508cm -12456cm -11647cm -11591cm -11408cm -1769cm -1There is absorption peak at the place.Described Type B is at about 3023cm -12924cm -12861cm -12453cm -11647cm -11590cm -11408cm -1768cm -1There is absorption peak at the place.
Adopt Perkin Elmer Diamond Differential Scanning CalorimeterAutosample equipment that A and B crystal formation are carried out differential thermal analysis, temperature range is 50 ℃-350 ℃, rate of heating is 10 ℃/minute, the result shows that the DSC collection of illustrative plates of A and B crystal formation is similar, the A crystal formation has endotherm(ic)peak near 320.678 ℃, the B crystal formation has endotherm(ic)peak near 320.68 ℃.
The invention also discloses the A crystal formation of preparation RS 25259-197 and the method for B crystal formation, these two kinds of methods are simple, are suitable for suitability for industrialized production, and generate crystal formation yield height.
The A crystal formation generally can prepare by the following method:
(1) RS 25259-197 is placed the Virahol of 10-30 times of Palonosetron bulking value and the mixed solvent of water;
(2) after the heating for dissolving, reheat evaporates the solvent volume about about 10%-35% or adds the Virahol of 5-10 times of Palonosetron bulking value again;
(3) cooling, crystallization filters, 80-90 ℃ vacuum-drying 4-6 hour, collect crystallisate.
As a kind of alternative plan, RS 25259-197 can be placed the Virahol of 10-30 times of RS 25259-197 bulking value (1 bulking value is defined as by every 1g RS 25259-197 and adds the 1ml solvent) and the mixed solvent of water, preferred 15-20 times of RS 25259-197 bulking value.The water yield is preferably the 1-8% of mixed solvent volume, is preferably 2-6%, more preferably about 4-5%.After heating made RS 25259-197 dissolving, the solvent volume about the about 10%-35% of heating evaporation or add the Virahol of 5-10 times of RS 25259-197 bulking value again was cooled to about 0-10 ℃, crystallization 2-5 hour, filter, 80-90 ℃ vacuum-drying 4-6 hour, collect crystallisate.
The B crystal formation generally can prepare by the following method:
(1) RS 25259-197 is placed the ethanol or the dimethyl formamide (DMF) of 30-60 times of RS 25259-197 bulking value;
(2) after heating makes it dissolving, cooling;
(3) stirring and crystallizing is filtered, 80-90 ℃ vacuum-drying 4-6 hour, collect crystallisate.
As a kind of alternative plan, RS 25259-197 can be placed the ethanol or the dimethyl formamide (DMF) of 30-60 times of RS 25259-197 bulking value (1 bulking value is defined as by every 1g RS 25259-197 and adds the 1ml solvent), preferred 40-50 times of RS 25259-197 bulking value.Heating is cooled to about 0-10 ℃ after making it dissolving, stirring and crystallizing 2-5 hour, filter, 80-90 ℃ vacuum-drying 4-6 hour, collect crystallisate.
Another object of the present invention provides a kind of pharmaceutical composition, A type or Type B RS 25259-197 crystallisate and at least a pharmaceutically acceptable carrier that it contains significant quantity can be used for treating moderate or highly cause the acute and tardy property nausea and vomiting that vomitting property chemotherapy causes.
RS 25259-197 obtains the approval of U.S. FDA in July, 2003, be used for preventing moderate and highly cause vomiting chemotherapy of tumors acute nausea and vomiting initial and that repeat a treatment and tardy property nausea and vomiting symptom, and to be first individually dosedly be used for treating the 5-HT3 receptor antagonist that moderate causes vomiting chemotherapy of tumors patient's tardy property symptoms of emesis by what FDA ratified.
But the pharmaceutical dosage form of above-mentioned approval is an injection liquid, and specification is 0.25mg/5ml.This means that patient must be in hospital undergoing treatment, and the injection meeting brings misery and inconvenience to patient, especially unfavorable for the patient who produces tardy property nausea and vomiting symptom after the chemotherapy.And oral administration can make things convenient for patient's administration, is beneficial to treatment.
RS 25259-197 A type disclosed by the invention and Type B crystallization have definite structure, and its crystallized form is highly stable, and tap density is good, can not transform automatically between these two crystal formations.Sealing was preserved more than half a year in 40 ℃ of accelerated tests and 50% humidity environment, and crystal formation is constant substantially, and content does not reduce, can be under lucifuge, cool place and drying conditions prolonged preservation, be suitable for preparing oral administered dosage form.Consider the absorption problem of oral administration, active ingredient hydrochloric acid Palonosetron A type and Type B crystalline dosage should be more than 0.25mg.
RS 25259-197 A type or the Type B crystalline pharmaceutical composition of containing disclosed in this invention, can be that tablet (as enteric coated tablet, coating tablet, film coated tablet, coated tablet, medicinal extract sheet, dispersible tablet, cut sheet etc.), hard capsule, soft capsule (capsule and pill), enteric coated capsule, sustained-release and controlled release formulation, slow releasing tablet, sustained release coating and other are any be fit to oral formulation for it.The carrier that the pharmacy that is fit to can go up acceptance can be starch, Mierocrystalline cellulose, talcum, sugar (lactose, glucose, sucrose etc.), dextrin, lime carbonate, magnesium oxide, N.F,USP MANNITOL, poly-methyl acrylate, Repone K, sodium-chlor, sorbyl alcohol, secondary calcium phosphate, croscarmellose sodium, Natvosol, gelatin, hydroxypropylcellulose, sodium alginate, carboxymethyl cellulose, carboxyethyl cellulose, colloid silica, Magnesium Stearate, hydrogenated vegetable oil, polyoxyethylene glycol, palmitostearate, citric acid, wherein one or more such as neusilin.In final pharmaceutical composition, the content of RS 25259-197 is 0.00001%-5%, preferred 0.01%-1.5%.
As a kind of selection, embodiment 10 discloses a kind of tablet, and every medicament RS 25259-197 A type crystalline content is 1%, and carboxymethyl cellulose level is 70%, and palmitostearate is 15%, and dextrin content is 10%, and neusilin content is 4%.
Embodiment 11 discloses a kind of capsule, and wherein RS 25259-197 Type B crystalline content is 1.5%, and lactose hydrous content is 10%, and the microcrystalline cellulose cellulose content is 75%, and croscarmellose sodium content is 8.5%, and Magnesium Stearate content is 5%.
Description of drawings
Accompanying drawing 1 is the powder x-ray diffraction spectrogram of RS 25259-197 A crystal formation
Accompanying drawing 2 is powder x-ray diffraction spectrograms of RS 25259-197 B crystal formation
Accompanying drawing 3 is infrared absorption patterns of RS 25259-197 A crystal formation
Accompanying drawing 4 is infrared absorption patterns of RS 25259-197 B crystal formation
Accompanying drawing 5 is DSC collection of illustrative plates of RS 25259-197 A crystal formation
Accompanying drawing 6 is DSC collection of illustrative plates of RS 25259-197 B crystal formation
Embodiment
The preparation one of embodiment 1 RS 25259-197 A crystal formation
Get RS 25259-197 5g, add 115ml Virahol and 4ml water, heating makes it dissolving.After treating the whole dissolvings of solid, continue heating, after air distillation goes out 36ml liquid, be cooled to 0 ℃, stir, crystallization 2 hours, after-filtration is separated out in crystallization, in 80 ℃ of vacuum-dryings 4 hours, gets the pure product 4.4g of crystallisate, and it is 99.7% that HPLC detects purity.
The preparation two of embodiment 2 RS 25259-197 A crystal formations
Get RS 25259-197 8g, add 124ml Virahol and 6.4ml water, heating makes it dissolving.After treating that solid all dissolves, add Virahol 54ml, be cooled to 0 ℃, stir, crystallization 4 hours, after-filtration is separated out in crystallization, in 80 ℃ of vacuum-dryings 4 hours, gets the pure product 7.56g of crystallisate, and it is 99.6% that HPLC detects purity.
The preparation one of embodiment 3 RS 25259-197 B crystal formations
Get RS 25259-197 5g, add 200ml ethanol, after heating made the solid dissolving, cooling 10 ℃ of stirring and crystallizing 2 hours, was filtered, in 80 ℃ of vacuum-dryings 4 hours, pure product 4.3 grams of crystallisate, it is 99.2% that HPLC detects purity.
The preparation two of embodiment 4 RS 25259-197 B crystal formations
Get RS 25259-197 5g, add 200ml dimethyl formamide (DMF), after heating made the solid dissolving, cooling 5 ℃ of stirring and crystallizing 4 hours, was filtered, in 80 ℃ of vacuum-dryings 4 hours, pure product 4.5 grams of crystallisate, it is 99.3% that HPLC detects purity.
Embodiment 5 RS 25259-197 A crystal formations are measured
The crystallisate powder of getting embodiment 1 preparation carries out X ray diffracting spectrum to be measured, and described A crystal formation is using Cu-K α radiation condition (λ=1.54059
Figure 2008100595276_66
), the x-ray diffractogram of powder when 2 θ angles are 0-50 ° in Prague spectrum data are as shown in table 1, wherein 2Tetha is 2 θ angles, d is a spacing, I/I 0Represent relative intensity, the per-cent that accounts for area under the intense line with area under a certain spectral line is represented.Characteristic peak as shown in Figure 1, its characteristic peak is expressed as 7.32 with spacing d (round up and get hundredths)
Figure 2008100595276_67
6.43
Figure 2008100595276_68
6.26
Figure 2008100595276_69
6.12 5.61
Figure 2008100595276_71
5.24
Figure 2008100595276_72
4.80
Figure 2008100595276_73
4.51
Figure 2008100595276_74
4.44
Figure 2008100595276_75
4.24
Figure 2008100595276_76
3.86
Figure 2008100595276_77
3.82
Figure 2008100595276_78
3.79
Figure 2008100595276_79
3.75
Figure 2008100595276_80
3.69
Figure 2008100595276_81
3.65
Figure 2008100595276_82
3.21 2.77
Figure 2008100595276_84
Characteristic peak herein is defined as I/I 0＞20%.
Table 1A crystal formation x-ray diffractogram of powder spectrum data
2-Theta d I/I0(％)
7.054 12.5219 5.2
10.413 8.4884 8.8
12.081 7.3202 33.5
12.323 7.1770 3.9
13.764 6.4287 56.8
14.134 6.2610 42.1
12.323 7.1770 3.9
14.444 6.1275 29.3
15.765 5.6167 96.0
16.921 5.2356 27.7
17.225 5.1438 18.5
18.454 4.8040 68.8
18.693 4.7429 19.7
19.663 4.5112 100.0
19.983 4.4398 70.1
20.262 4.3792 7.1
20.932 4.2404 21.9
21.269 4.1740 3.6
22.383 3.9688 1.2
22.995 3.8646 20.5
23.271 3.8194 57.4
23.465 3.7882 34.7
23.735 3.7456 30.3
24.080 3.6927 25.4
24.392 3.6462 28.7
24.791 3.5885 14.8
25.376 3.5070 16.0
26.053 3.4174 1.3
26.342 3.3806 5.0
12.323 7.1770 3.9
26.713 3.3345 13.0
26.784 3.3258 13.0
27.731 3.2143 25.1
29.163 3.0597 7.9
29.359 3.0397 8.8
29.760 2.9996 2.4
30.194 2.9575 9.7
30.934 2.8884 0.4
31.217 2.8629 2.7
31.402 2.8465 10.8
31.595 2.8295 17.8
31.839 2.8084 14.8
31.900 2.8032 12.3
32.081 2.7877 14.0
32.247 2.7738 27.1
32.851 2.7241 4.0
33.621 2.6635 11.6
33.837 2.6469 10.6
34.226 2.6178 6.2
34.765 2.5784 2.3
35.177 2.5492 4.3
35.827 2.5044 3.3
29.359 3.0397 8.8
35.924 2.4979 12.2
36.087 2.4869 3.5
36.667 2.4489 5.1
36.837 2.4380 7.4
36.923 2.4325 8.9
37.230 2.4131 3.8
37.513 2.3956 4.1
37.848 2.3752 4.5
38.044 2.3634 5.1
38.763 2.3212 9.9
38.915 2.3124 12.9
39.096 2.3021 7.0
39.890 2.2582 5.9
40.108 2.2464 5.3
41.455 2.1765 2.8
42.435 2.1284 7.0
42.607 2.1202 11.1
43.320 2.0870 7.2
44.267 2.0445 5.4
44.524 2.0333 7.9
45.058 2.0104 7.5
46.226 1.9623 14.0
39.096 2.3021 7.0
46.481 1.9521 13.3
48.267 1.8840 4.9
48.573 1.8728 7.0
48.718 1.8676 3.9
49.240 1.8490 4.2
Embodiment 6 RS 25259-197 B crystal formations are measured
The crystallisate powder of getting embodiment 4 preparations carries out X ray diffracting spectrum to be measured, and described B crystal formation is using Cu-K α radiation condition (λ=1.54059 ), the x-ray diffractogram of powder when 2 θ angles are 0-50 ° in Prague spectrum data are as shown in table 2,2-Theta is 2 θ angles, d is a spacing, I/I 0Represent relative intensity, the per-cent that accounts for area under the intense line with area under a certain spectral line is represented.Characteristic peak as shown in Figure 2, its characteristic peak is expressed as 6.81 with spacing d (round up and get hundredths)
Figure 2008100595276_86
6.46
Figure 2008100595276_87
6.25
Figure 2008100595276_88
5.76
Figure 2008100595276_89
5.49
Figure 2008100595276_90
5.05
Figure 2008100595276_91
4.81
Figure 2008100595276_92
4.45
Figure 2008100595276_93
3.83 3.65
Figure 2008100595276_95
3.58
Figure 2008100595276_96
3.55 3.23
Figure 2008100595276_98
2.83
Figure 2008100595276_99
Characteristic peak herein is defined as I/I 0＞20%.
Table 2B crystal formation x-ray diffractogram of powder spectrum data
2-Theta d I/I 0(％)
7.062 12.5070 11.7
9.922 8.9078 11.3
11.357 7.7849 6.4
12.982 6.8137 67.4
13.699 6.4587 21.2
14.162 6.2488 66.7
15.381 5.7561 27.5
16.138 5.4878 25.3
16.342 5.4197 8.2
2-Theta d I/I 0(％)
17.537 5.0529 22.7
18.438 4.8082 63.0
19.941 4.4491 100.0
21.320 4.1642 4.5
21.921 4.0514 9.4
22.119 4.0156 16.6
23.182 3.8337 36.1
23.560 3.7732 9.2
24.399 3.6452 25.3
24.838 3.5817 35.1
25.100 3.5450 30.9
26.198 3.3988 4.4
27.561 3.2338 23.2
28.919 3.0849 13.5
29.680 3.0076 6.6
31.500 2.8378 17.3
31.641 2.8254 24.4
31.964 2.7977 5.4
32.402 2.7608 12.8
32.618 2.7431 6.7
32.402 2.7608 12.8
33.703 2.6572 3.4
34.141 2.6241 3.4
34.542 2.5945 4.8
35.499 2.5267 4.6
35.903 2.4992 5.1
37.280 2.4101 4.4
37.620 2.3890 3.6
37.899 2.3721 3.7
38.762 2.3212 9.0
39.700 2.2685 3.7
40.638 2.2183 5.9
42.321 2.1339 3.4
43.421 2.0824 5.5
44.899 2.0172 11.7
45.121 2.0078 11.7
45.880 1.9763 9.5
46.118 1.9666 14.6
47.743 1.9034 3.2
Embodiment 7A crystal formation infrared absorption spectrum
With the KCl pressed disc method Palonosetron A crystal formation is measured infrared absorption spectrum, the A crystal formation is at about 3025cm -12924cm -12861cm -12508cm -12456cm -11647cm -11591cm -11408cm -1769cm -1There is absorption peak at the place.Accompanying drawing 3 is the infrared absorption pattern of A crystal formation.
Embodiment 8B crystal formation infrared absorption spectrum
With the KCl pressed disc method Palonosetron B crystal formation is measured infrared absorption spectrum, the B crystal formation at described approximately Type B at about 3023cm -12924cm -12861cm -12453cm -11647cm -11590cm -11408cm -1768cm -1There is absorption peak at the place.Accompanying drawing 4 is the infrared absorption pattern of B crystal formation.
Embodiment 9 differential thermal analysis (DSC)
Adopt Perkin Elmer Diamond Differential Scanning CalorimeterAutosample equipment that A or B crystal formation are carried out calorimetric analysis, temperature range is 50 ℃-350 ℃, rate of heating is 10 ℃/minute, the result shows that the DSC collection of illustrative plates of A and B crystal formation is similar, the A crystal formation has endotherm(ic)peak near 320.678 ℃, the B crystal formation has endotherm(ic)peak near 320.68 ℃.。Accompanying drawing 5 is the DSC collection of illustrative plates of A crystal formation, and accompanying drawing 6 is the DSC collection of illustrative plates of B crystal formation.
The preparation of embodiment 10 RS 25259-197 A type crystallization tablets
A kind of tablet, wherein RS 25259-197 A type crystalline content is 1%, and carboxymethyl cellulose level is 70%, and palmitostearate is 15%, and dextrin content is 10%, neusilin content is 4%.Every tablet of medicament contains the about 0.5mg of RS 25259-197 A type crystallization.
The capsular preparation of embodiment 11 RS 25259-197 Type B crystallizations
A kind of capsule, wherein RS 25259-197 Type B crystalline content is 1.5%, and lactose hydrous content is 10%, and the microcrystalline cellulose cellulose content is 75%, and croscarmellose sodium content is 8.5%, Magnesium Stearate content is 5%.The hydrochloric Palonosetron Type B of every capsules crystallization 1mg.

Claims (17)

1. the A crystal formation of RS 25259-197, the X-ray diffraction of its powder has following characteristic peak: d is expressed as 7.32 with spacing
Figure FSB00000076547800011
6.43
Figure FSB00000076547800012
6.26
Figure FSB00000076547800013
6.12
Figure FSB00000076547800014
5.61
Figure FSB00000076547800015
5.24 4.80
Figure FSB00000076547800017
4.51
Figure FSB00000076547800018
4.44
Figure FSB00000076547800019
4.24
Figure FSB000000765478000110
3.86
Figure FSB000000765478000111
3.82
Figure FSB000000765478000112
3.79 3.75 3.69
Figure FSB000000765478000115
3.65 3.21
Figure FSB000000765478000117
2.77
Figure FSB000000765478000118
2. the A crystal formation of RS 25259-197 according to claim 1, it is characterized in that: described A crystal formation infrared absorption spectrum is at 3025cm -12924cm -12861cm -12508cm -12456cm -11647cm -11591cm -11408cm -1769cm -1There is absorption peak at the place.
3. the A crystal formation of RS 25259-197 according to claim 1, it is characterized in that: the DSC collection of illustrative plates of described A crystal formation has been located endotherm(ic)peak at 320.678 ℃.
4. prepare the method for RS 25259-197 A crystal formation as claimed in claim 1, comprise the steps:
(1) RS 25259-197 is placed the Virahol of 10-30 times of Palonosetron bulking value and the mixed solvent of water;
(2) after the heating for dissolving, reheat evaporates the 10%-35% solvent volume or adds the Virahol of 5-10 times of Palonosetron bulking value again;
(3) cooling, crystallization filters, 80-90 ℃ vacuum-drying 4-6 hour, collect crystallisate.
5. method according to claim 4 is characterized in that: the mixed solvent volume of Virahol and water is a 15-20 times of Palonosetron bulking value.
6. method according to claim 4 is characterized in that: the content of water accounts for the 1-8% of mixed solvent volume.
7. method according to claim 6 is characterized in that: the content of water accounts for the 2-6% of mixed solvent volume.
8. method according to claim 7 is characterized in that: the content of water accounts for the 4-5% of mixed solvent volume.
9. method according to claim 4 is characterized in that: in the step (3) solvent temperature is cooled to 0-10 ℃.
10. method according to claim 4 is characterized in that: the crystallization time is 2-5 hour in the step (3).
11. a pharmaceutical composition, it contains the RS 25259-197 A type crystallisate as claimed in claim 1 and at least a pharmaceutically acceptable carrier of significant quantity.
12. pharmaceutical composition according to claim 11 is characterized in that: to be that tablet, hard capsule, soft capsule, enteric coated capsule, sustained-release and controlled release formulation, slow releasing tablet, sustained release coating and other are any be fit to oral formulation to the formulation of described pharmaceutical composition.
13. pharmaceutical composition according to claim 11 is characterized in that: the carrier that described pharmacy can go up acceptance is wherein one or more of starch, Mierocrystalline cellulose, talcum, sugar, dextrin, lime carbonate, magnesium oxide, N.F,USP MANNITOL, poly-methyl acrylate, Repone K, sodium-chlor, sorbyl alcohol, secondary calcium phosphate, Natvosol, gelatin, hydroxypropylcellulose, sodium alginate, carboxymethyl cellulose, carboxyethyl cellulose, colloid silica, Magnesium Stearate, hydrogenated vegetable oil, polyoxyethylene glycol, palmitostearate, citric acid or neusilin.
14. pharmaceutical composition according to claim 13 is characterized in that: described sugar is lactose, glucose or sucrose.
15. pharmaceutical composition according to claim 11 is characterized in that: the content of RS 25259-197 is 0.00001-5%.
16. pharmaceutical composition according to claim 15 is characterized in that: the content of RS 25259-197 is 0.01%-1.5%.
17. pharmaceutical composition according to claim 16, it is characterized in that: described pharmaceutical composition is a tablet, every medicament RS 25259-197 A type crystalline content is 1%, carboxymethyl cellulose level is 70%, palmitostearate is 15%, dextrin content is 10%, and neusilin content is 4%.
CN2008100595276A 2008-01-24 2008-01-24 Crystal system of chlorhydric acid palonosetron and preparation method thereof Expired - Fee Related CN101255157B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2008100595276A CN101255157B (en) 2008-01-24 2008-01-24 Crystal system of chlorhydric acid palonosetron and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2008100595276A CN101255157B (en) 2008-01-24 2008-01-24 Crystal system of chlorhydric acid palonosetron and preparation method thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN200910215193.1A Division CN101792441B (en) 2008-01-24 2008-01-24 Crystal forms of palonosetron hydrochloride and preparation method thereof

Publications (2)

Publication Number Publication Date
CN101255157A CN101255157A (en) 2008-09-03
CN101255157B true CN101255157B (en) 2010-10-13

Family

ID=39890317

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008100595276A Expired - Fee Related CN101255157B (en) 2008-01-24 2008-01-24 Crystal system of chlorhydric acid palonosetron and preparation method thereof

Country Status (1)

Country Link
CN (1) CN101255157B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009087643A1 (en) * 2008-01-11 2009-07-16 Natco Pharma Limited Novel crystalline forms of palonosetron hydrochloride
US20120267533A1 (en) * 2009-06-30 2012-10-25 Ranbaxy Laboratories Limited Processes for the preparation of form i and form ii of palonosetron hydrochloride
CN114315822A (en) * 2021-12-23 2022-04-12 北大医药股份有限公司 Palonosetron hydrochloride hydrate crystal form and preparation method thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ravikumar and Sridhar.An orthorhombic polymorph of palonosetron hydrochloride.Acta Crystallographica Section E onlineE63.2007,E63o1404-o1406. *
刘慧颖.盐酸帕洛诺司琼合成及质量研究.中国优秀硕士学位论文集.2007,1-48. *

Also Published As

Publication number Publication date
CN101255157A (en) 2008-09-03

Similar Documents

Publication Publication Date Title
JP3760264B2 (en) Aripiprazole hydrate, aripiprazole anhydrous crystals, methods for producing them and formulations containing them
CN100546985C (en) Febuxotat microcrystal and composition thereof
CN108066358A (en) Pharmaceutical composition for pharmaceutical composition for preventing or treating the cancer of the brain and preparation method thereof and for inhibiting cancer of the brain transfer
CN102933551A (en) Hydrated crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
CN102272124A (en) New crystal form of sunitinib malate
CN103113405B (en) Benfotiamine polymorphs body, preparation method and application thereof
CN101255157B (en) Crystal system of chlorhydric acid palonosetron and preparation method thereof
CN103237547A (en) Crystalline naloxol-eg conjugate
CN101597272B (en) Sodium salt compound of Iguratimod, preparation method thereof and pharmaceutical use thereof
US20080145425A1 (en) Pharmaceutical composition of zolpidem
JP2022526822A (en) Borsicrib polymorphs, and how to make and use them
CN110291079A (en) With pyridine acyl piperidines 5-HT1FThe relevant composition of agonist and method
CN107522625A (en) A kind of dezocine A crystal formations and preparation method thereof
CN101102994A (en) Polymorphs of memantine hydrochloride
WO2018188495A1 (en) Compound of eoc315 mod.i crystal form and preparation method therefor
CN101792441B (en) Crystal forms of palonosetron hydrochloride and preparation method thereof
CN101993417A (en) Stable novel crystal form of dimemorfan phosphate
CN103073543A (en) Preparation method and application of tropisetron citrate crystal form I
AU2015282909B2 (en) Novel polymorphic form of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of Alzheimer's
CN102249978A (en) KY crystal form of Atorvastatin calcium and preparation method thereof
CN102093387B (en) Crystal compound of 4,5,6,7-tetrahydro-isoxazolo[5,4-c]pyridine-3-alcohol-hydrate
CN103360392A (en) Dolasetron mesylate compound
CN104098575B (en) Brilliant type of a kind of Epinastine Hydrochloride and its production and use
CN103214459A (en) Pantoprazole sodium crystalline compound, pharmaceutical composition and preparation method thereof
CN103351387A (en) Preparation method of pyrroloquinolinequinone lithium salt crystal and applications thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20101013

Termination date: 20220124

CF01 Termination of patent right due to non-payment of annual fee